SEC Filing Summary: Salarius Pharmaceuticals, Inc.
Business Context and Reporting Period
This Form 8-K was filed by Salarius Pharmaceuticals, Inc. (SLRX) on October 6, 2020, reporting an event that occurred on October 5, 2020. The registrant is a Delaware corporation with its principal executive offices in Houston, Texas, and its common stock is listed on The Nasdaq Stock Market LLC.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. The only financial metric disclosed is the stock price performance triggering the regulatory notice.
Material Changes and Events
- Delisting Notice: On October 5, 2020, the Company received a notice from Nasdaq stating that the average closing price of its common stock fell below $1.00 per share over the prior 30 consecutive trading days.
- Regulatory Breach: This price decline violated Nasdaq Listing Rule 5450(a)(1), known as the Minimum Bid Requirement.
- Compliance Timeline: The Company has been granted an initial 180-calendar-day period to regain compliance, ending on April 5, 2021.
Outlook, Risks, and Management Commentary
Management intends to actively monitor the closing bid price and evaluate available options to regain compliance. To maintain listing status, the stock must close at or above $1.00 per share for a minimum of ten consecutive business days before the April 5, 2021 deadline. If the Company fails to comply within the initial 180 days, it may be eligible for an additional 180-day period, provided it meets other listing standards such as the market value of publicly held shares. There is no assurance that the Company will successfully regain compliance or avoid delisting. The Company retains the right to appeal any delisting determination to a Hearings Panel.
Key Facts for Investor Verification
- Verify the current trading price of SLRX to assess the likelihood of meeting the $1.00 average closing price requirement.
- Monitor the Company's announcements regarding potential reverse stock splits or other corporate actions intended to increase the share price.
- Check for any subsequent filings indicating whether the Company has met the ten-day consecutive closing price requirement by April 5, 2021.
- Review the Company's most recent 10-K or 10-Q for liquidity and cash runway, as this filing does not contain financial statements.